Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HELSINKI, FINLAND, 28 May 2013: Plexpress, developer of the innovative TRAC platform for high-throughput gene expression analysis, has launched a specific ADME-Tox service for canine preclinical drug candidate screening, in collaboration with Admescope. The new TRACPACK DOG INDUCTION screening service provides canine cytochrome P450 (CYP) mRNA analysis using primary dog hepatocytes followed by CYP enzyme activity measurements. Hepatocytes from three separate donors are used, generating CYP mRNA expression and protein activity data produced in line with the FDA recommendations for human hepatocytes.
Reliable canine-specific CYP analysis is important in order to improve predictions for human pharmaceutical development (1). The validated Dog ADME-Tox mRNA panel from Plexpress includes all relevant CYP targets and reference genes, ready-to-analyze in a single well for high throughput multiplexing. Additional genes can also be included according to study needs.
The combination of high sample throughput with gene multiplexing increases assay speed while minimizing technical variation, making TRAC highly cost- and time-efficient, boosting efficiency in CRO and Pharma laboratories.
In addition to mRNA analysis, TRACKPACK DOG INDUCTION also offers subsequent CYP activity measurements thanks to Plexpress’ collaboration with Admescope. To investigate metabolites, study compounds are exposed for 72h, after which substrates for CYP-specific model reactions are added, and the samples analyzed.
TRACPACK DOG INDUCTION provides a single, integrated service for all canine CYP induction analysis, ensuring consistent and reliable data. All TRACPACK results are delivered electronically, in an easy-to-use, summarized report for quick and easy data analysis.
For further information on TRACPACK DOG INDUCTION services, please visit the webpage, or the Plexpress website at www.plexpress.com.
1. Martinez, M.N. et al, Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metab Rev. 2013 May;45(2):218-30
Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.
Help employers find you! Check out all the jobs and post your resume.